Intelligent Docetaxel Liposomal Injections for Personalized Cancer Treatment

The present invention relates to a novel system that integrates docetaxel liposomal injections with advanced technologies like AI, IoT, blockchain, and new materials to create a more effective and personalized cancer treatment approach.

The original patent provided a composition of docetaxel liposomal injection with high drug loading, but it had limitations in terms of targeted delivery, patient monitoring, and supply chain integrity. The new inventive concept addresses these limitations by incorporating synergistic combinations of distinct technologies to create a more powerful system.

The new system comprises a docetaxel liposomal composition, an AI-powered delivery mechanism that optimizes the composition's residence time in blood, an IoT-enabled monitoring system that tracks the patient's response to the treatment, a blockchain-secured tracking mechanism that ensures the authenticity and integrity of the composition throughout the supply chain, and a novel material for docetaxel liposomal compositions that enhances the composition's stability and bioavailability. The AI-driven dosing algorithm optimizes the composition's release profile based on the patient's individual needs.

The new claims introduce a synergistic combination of advanced technologies that create a more effective and personalized cancer treatment approach, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials with the docetaxel liposomal composition provides a novel and non-obvious solution.

Other ways to implement the inventive concept include using different AI algorithms for personalized dosing, integrating the system with wearable devices for real-time patient monitoring, or using alternative blockchain platforms for secure tracking. The novel material for docetaxel liposomal compositions could be modified to include other excipients or nanoparticles for enhanced stability and bioavailability.

The intelligent docetaxel liposomal injections have significant commercial potential in the oncology market, particularly in personalized cancer treatment. The system's ability to optimize treatment outcomes, reduce side effects, and ensure supply chain integrity makes it an attractive solution for pharmaceutical companies, hospitals, and patients.